Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein
Author(s): Dirk Roymans, Hendrik L. De Bondt, Eric Arnoult, et al
PNAS January 5, 2010, vol. 107 no. 1 308-313 doi 10.1073/pnas.0910108106: Manuscript
The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis
Author(s): Andreas H. Diacon, Alexander Pym, Martin Grobusch et al
NEJM 2009 Jun 4; Volume 360; Number 23:2397-2405 Manuscript
Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection
Author(s): Christophe Hézode, Nicole Forestier, Geoffrey Dusheiko et al
NEJM 2009 Apr 30;Volume 360; Number 18:1839-1850 Manuscript
Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection
Author(s): John G. McHutchison, Gregory T. Everson, Stuart C. Gordon et al
NEJM 2009 Apr 30; Volume 360; Number 18:1827-1838 Manuscript
Diarylquinolines Are Bactericidal for Dormant Mycobacteria as a Result of Disturbed ATP Homeostasis
Author(s): Anil Koul, Luc Vranckx, Najoua Dendouga, et al
J. Biol. Chem., Vol. 283, Issue 37, 25273-25280, September 12, 2008 Manuscript
Safety, Tolerability, and Preliminary Efficacy of 48 Weeks of Etravirine Therapy in a Phase IIb Dose-Ranging Study Involving Treatment-Experienced Patients with HIV-1 Infection
Author(s): Julio Montaner, Patrick Yeni, Nathan N. Clumeck, et al
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial
Author(s): Madruga JV, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A, Pialoux G, Wilkin T, Peeters M, Vingerhoets J, de Smedt G, Leopold L, Trefiglio R, Woodfall B, on behalf of the DUET-1 study group
The Lancet - Vol. 370, Issue 9581, 07 July 2007, Pages 29-38 Manuscript
Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial
Author(s): José Valdez Madruga, Daniel Berger, Marilyn McMurchie et al
Diarylquinolines target subunit c of mycobacterial ATP synthase
Author(s): Anil Koul, Najoua Dendouga, Karen Vergauwen et al
Nature Chemical Biology 3, 323 - 324 (2007): Manuscript
Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains
Author(s): Céline Mordanta, Benoit Schmitta, Elisabeth Pasquiera, et al
European Journal of Medicinal Chemistry Volume 42, Issue 5, May 2007, Pages 567-579 Manuscript
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials
Author(s): Clotet, Bonaventura; Bellos, Nicholas; Molina, Jean-Michel; et al
TMC125 Displays a High Genetic Barrier to the Development of Resistance: Evidence from in vitro selection experiments
Author(s): Johan Vingerhoets, Hilde Azijn, Els Fransen, Inky De Baere, Liesbet Smeulders, Dirk Jochmans, Koen Andries, Rudi Pauwels, and Marie-Pierre de Bethune
TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial
Author(s): Keikawus Arasteh, Nathan Clumeck, Anton Pozniak, Adriano Lazzarin, Sandra De Meyer, Heidi Muller, Monika Peeters, Alex Rinehart, Eric Lefebvre for the TMC114-C207 Study Team
TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant HIV type 1
Author(s): Koen Andries, Hilde Azijn, Theo Thielemans, ...
Antimicrobial Agents and Chemotherapy, Dec 2004, p 4680-4686
TMC125, a novel next generation non-nucleoside reverse transcriptase inhibitor active against non-nucleoside reverse transcriptase inhibitor-resistant HIV-1
Author(s): K. Andries, H. Azijn, T. Thielemans et al
Antimicrobial Agents and Chemotherapy, December 2004, p. 4680-4686, Vol. 48, No. 12
Manuscript
Comparative Efficacy of Topical Therapy with a Slow-Release Mucoadhesive Buccal Tablet Containing Miconazole Nitrate Versus Systemic Therapy With Ketoconazole in HIV-Positive Patients With Oropharyngeal Candidiasis
Author(s): J. Van Roey, M. Haxaire, M. Kamya, I. Lwanga, E. Katabira
J Acquir Immune Defic Syndr, Vol 35, No 2, February 1 2004
Manuscript
An open-label assessment of TMC125 - a new, next generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance
Author(s): B. Gazzard, A. Pozniak, W. Rosenbaum et al
